


U-73122

Cat. No.:	HY-13419		
CAS No.:	112648-68-7		
Molecular Formula:	C ₂₉ H ₄₀ N ₂ O ₃		
Molecular Weight:	464.64		
Target:	Phospholipase; Lipoxygenase; Ferroptosis		
Pathway:	Metabolic Enzyme/Protease; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 10 mg/mL (21.52 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1522 mL	10.7610 mL	21.5220 mL
		5 mM	0.4304 mL	2.1522 mL	4.3044 mL
10 mM		0.2152 mL	1.0761 mL	2.1522 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 0.5% CMC-Na/saline water Solubility: 10 mg/mL (21.52 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.62 mg/mL (1.33 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.62 mg/mL (1.33 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC ₅₀ of 1-2.1 μM for PLC.
IC₅₀ & Target	5-LOX
In Vitro	U-73122 potently inhibits receptor-coupled activation of PLC in membranes isolated from PMNs ^[1] . U-73122 inhibits N-formyl-methionyl-leucyl-phenylalanine-induced aggregation of human polymorphonuclear neutrophils (PMN) and the associated production of IP ₃ and diacylglycerol ^[2] . U-73122 markedly inhibits inositol phosphate release elicited by either

oxotremorine-M or guanosine-5'-O-(3-thiotriphosphate) than that induced by added Ca²⁺ in digitonin-permeabilized cells^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

U73122 significantly attenuates TNF- α mRNA expression, has no effect on sham animals, but significantly increases heart work and rate of contraction and relaxation without affecting heart rate in endotoxemic mice^[4]. U73122 (400 nM/ μ L) significantly reduces total lordosis durations, compared to vehicle infusions to the VTA, of oestradiol and progesterone-primed hamsters. VTA infusions of U73122 do not alter motor behaviour of hamsters in the activity monitor, but there is a significant effect of muscimol to decrease total number of beam breaks compared to hamsters administered SKF38393^[5]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

Agonist-induced production of IP₃ in PMN is measured by use of the competitive radiobinding assay. PMN (2×10^6 - 10^7) in 0.2 mL of phosphate-buffered saline, pH 7.4 [NaCl (138 mM), Na₂HPO₄ (8.1 mM), KH₂PO₄ (1.5 mM), KCl (2.7 mM), CaCl₂ (1.0 mM), MgCl₂ (1.0 mM) and glucose (0.1%, w/v)] are incubated in conical polypropylene tubes at 37°C in a shaking water bath. U-73122 or U-73343 is added (in 1 μ L of DMSO) 3 min before the addition of agonist, FMLP (0.1 μ M) plus cytochalasin B (5 μ g/mL). FMLP and cytochalasin B are added in 1 μ L each of DMSO and ethanol, respectively. Appropriate vehicle controls are included in each experiment. PMN incubation mixtures are quenched with the addition of 0.07 mL of ice-cold TCA (20%, w/v) and a portion (0.2 mL) of the TCA extract is processed for the measurement of IP₃ by competitive radiobinding as described above for platelets.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[5]

Hamsters are hormone-primed with 17 β -oestradiol at h 0 and progesterone at h 45. At h 48, hamsters are pretested for motor behaviour, followed by sexual behaviour testing, and bilateral infusions of U73122 (400 nM/ μ L) or saline vehicle. Thirty minutes after infusions, hamsters are re-tested for sexual behaviour (post inhibitor infusion test) and, immediately after testing, infused bilaterally with SKF38393 (100 ng/ μ L), muscimol (100 ng/ μ L), or saline vehicle. Thirty minutes after the agonist or vehicle infusions, lordosis and motor behaviour of hamsters is reassessed (post agonist infusion test). All hamsters are assigned to one pretreatment condition, U73122 or vehicle, and are tested once a week for 3 weeks until all infusion conditions (SKF38393, muscimol or vehicle), are received. The order in which hamsters receive SKF38393, muscimol or vehicle infusions is counterbalanced across the group.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Adv Funct Mater. 2019, 1808556.
- Nat Commun. 2022 Nov 10;13(1):6796.
- Mol Cell. 2023 Jan 14;S1097-2765(22)01217-5.
- J Exp Med. 2022 May 2;219(5):e20212414.
- Cell Death Differ. 2022 Jun 20.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Smith RJ, et al. Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J Pharmacol Exp Ther. 1990 May;253(2):688-97.

[2]. Bleasdale JE, et al. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J

[3]. Thompson AK, et al. The aminosteroid U-73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. A role for Gp in receptor compartmentation. J Biol Chem. 1991 Dec 15;266(35):23856-62.

[4]. Peng T, et al. Disruption of phospholipase Cgamma1 signalling attenuates cardiac tumor necrosis factor-alpha expression and improves myocardial function during endotoxemia. Cardiovasc Res. 2008 Apr 1;78(1):90-7. Epub 2007 Dec 12.

[5]. Frye CA, et al. In the ventral tegmental area, the membrane-mediated actions of progestins for lordosis of hormone-primed hamsters involve phospholipase C and protein kinase C. J Neuroendocrinol. 2007 Sep;19(9):717-24.

[6]. Hörnig M, et al. Inhibition of 5-lipoxygenase by U73122 is due to covalent binding to cysteine 416. Biochim Biophys Acta. 2012 Feb;1821(2):279-86.

[7]. Xie W, et al. 3Beta-hydroxy-6-aza-cholestane and related analogues as phosphatidylinositol specific phospholipase C (PI-PLC) inhibitors with antitumor activity. Bioorg Med Chem. 2000 Apr;8(4):699-706.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA